Limosilactobacillus reuteri DSM-17938 for preventing cough in adults with mild allergic asthma: A double-blind randomized placebo-controlled cross-over study

Tuesday, January 25th, 2022

This proof-of-concept study examined the systemic effects of Limosilactobacillus reuteri DSM-17938 versus placebo on capsaicin-evoked coughs in patients with mild allergic asthma. The primary endpoint was the change in maximum number of coughs evoked at any dose of capsaicin (Emax) following 4 weeks of treatment. Cough-related secondary endpoints were changes in the capsaicin dose evoking half the Emax, two coughs, five coughs, and full dose response curves. The number of coughs in the first 15 seconds following each of inhalation of capsaicin was counted and verified using the Vitalograph VitaloJAK cough monitor.